Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal Cancer
Liliana Bustamante, MD, and Richard Kim, MD, discuss circulating tumor DNA as a potential prognostic biomarker for patients with colorectal cancer.
As part of the Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, of Florida Cancer Specialists in Fort Myers, Florida, and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer.
In the video series, Bustamante and Kim discussed the following:
- Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases
- Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases
- ctDNA as a Biomarker in CRC
- ctDNA Assays in CRC: Interpreting Clinical Findings
- ctDNA Assays in CRC: Impact on Clinical Practice
- Next Steps in Using ctDNA as a Biomarker in CRC
- Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer
To watch more videos in the CancerNetwork® Between the Lines™ series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
